David F. Melcher
David F. Melcher's purchase track record
How the stock did after each of David F. Melcher's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/23/2025 | EMBC | $106K | +36.0% | +39.3% | +13.8% |
| 2/25/2025 | EMBC | $178K | -14.5% | +9.3% | +8.6% |
| 2/12/2024 | EMBC | $33K | -4.3% | +0.7% | +6.4% |
| 9/8/2023 | EMBC | $98K | +13.2% | -12.0% | +14.9% |
| 2/15/2023 | EMBC | $101K | -14.3% | -41.8% | +6.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
BDX Revello Stent Trial Success, Revenue Up 5.4%, Earnings Down 34%. The company announced that its Revello stent achieved strong results in the AGILITY trial for peripheral artery disease patients. Revenue rose 5.4% year‑over‑year, but net earnings fell 34.3%, reflecting higher costs or lower margins. The dividend yield sits at 1.59% and analysts see a target of $194, while the stock trades near the top of its 52‑week range.
Transaction History
| EMBC | ▲ Buy | Open Market | 10,000 | $106K | 5/23/2025 | View on chart |
| EMBC | ▲ Buy | Open Market | 13,000 | $178K | 2/25/2025 | View on chart |
| EMBC | ▲ Buy | Grant | 17,450 | $0 | 2/12/2025 | View on chart |
| EMBC | ▲ Buy | Open Market | 2,000 | $33K | 2/12/2024 | View on chart |
| EMBC | ▲ Buy | Grant | 3,437 | $0 | 2/7/2024 | View on chart |
| EMBC | ▲ Buy | Grant | 11,455 | $0 | 2/7/2024 | View on chart |
| EMBC | ▲ Buy | Open Market | 6,233 | $98K | 9/8/2023 | View on chart |
| EMBC | ▲ Buy | Open Market | 3,100 | $101K | 2/15/2023 | View on chart |
| EMBC | ▲ Buy | Grant | 6,979 | $0 | 2/9/2023 | View on chart |
| EMBC | ▲ Buy | Grant | 2,094 | $0 | 2/9/2023 | View on chart |
| EMBC | ▲ Buy | Grant | 1,954 | $0 | 12/6/2022 | View on chart |
| EMBC | ▲ Buy | Grant | 6,024 | $0 | 4/1/2022 | View on chart |
| BDX | ▲ Buy | Grant | 820 | $0 | 1/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Concentra Group Hits 52-Week High Amid Medical Services Trends
Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.
Concentra Group Hits 52-Week High Amid Medical Services Trends. Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.